Compare Amgen, Inc. (AMGN) vs Eni SpA (E) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Eni SpA — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Eni SpA trades at $48.42 (market cap $68.81B). The key difference: Amgen, Inc. is far larger — about 2.9× Eni SpA's market cap, and Eni SpA pays the higher dividend (5.12%). Which is the better fit depends on your goals.
| AMGN | E | |
|---|---|---|
Market Cap | $196.12B | $68.81B |
Sector | Health | Energy |
52-Week High | $388.16 | $57.61 |
52-Week Low | $271.18 | $32.93 |
Enterprise Value | $241.41B | $87.72B |
Dividend Yield | 2.77% | 5.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
E trades at $47.72, down 0.4% on the day, with a bullish technical signal despite recent earnings volatility. The company maintains stable cash flows with $238M net cash flow in 2025 and a dividend yield of 1.3%. Recent strategic moves include lithium investments in Chile and energy trading partnerships, diversifying beyond traditional oil and gas operations. Valuation metrics appear attractive with P/E of 21.05 and P/S of 0.77, though revenue has declined from $132.5B in 2022 to $82.2B in 2025.
The outlook balances value opportunities against execution risks. Analysts show cautious optimism with 34.6% buy ratings, but declining revenue and margin pressure pose challenges. Key catalysts include successful integration of new energy ventures and oil price stability, while geopolitical tensions and energy transition costs represent significant headwinds for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →
